Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Britain Approves Controversial Gene-editing Technique

By Drug Discovery Trends Editor | February 1, 2016

Britain’s fertility regulator has approved a scientist’s request to edit the human genetic code in an effort to fight inherited diseases – but critics fear the new technique crosses too many ethical boundaries.
 
The Human Fertilisation and Embryology Authority announced Monday it has granted a research application to a team led by scientist Kathy Niakan to try to understand the genes that human embryos need to develop successfully.
 
Scientists say gene-editing techniques could one day lead to treatments for conditions like HIV, which causes AIDS, and inherited diseases like muscular dystrophy and sickle cell disease.
 
Niakan, of the Francis Crick Institute, plans to use gene editing to analyze the first week of an embryo’s growth.
 
This research will “enhance our understanding of (in vitro fertilization) success rates, by looking at the very earliest stage of human development,” said Paul Nurse, director of the Francis Crick Institute.
 
Peter Braude, an emeritus professor of obstetrics and gynecology at King’s College London, said the mechanisms being investigated by Niakan and colleagues “are crucial in ensuring healthy, normal development and implantation” and could help doctors understand how to improve in vitro fertilization rates and prevent miscarriages.
 
Braude is not connected to Niakan’s research.
 
Last year, Chinese researchers made the first attempt at modifying genes in human embryos. Their laboratory experiment didn’t work – the embryos weren’t viable – but raised the prospect of altering genes to repair the genes of future generations.
 
The gene-editing technique was developed partly in the U.S. and scientists there have experimented with the method in animals and in human cells in the laboratory. Gene editing has not been used for any kinds of patient therapies just yet.
 
Around the world, laws and guidelines vary widely about what kind of research is allowed on embryos, since it could change the genes of future generations. In the U.S., the National Institutes of Health won’t fund this kind of research but private funding is allowed.
 
Critics warn that tweaking the genetic code this way could eventually produce a slippery slope that eventually leads to so-called “designer babies,” where parents seek taller, stronger or smarter children with specific physical characteristics.
 
“This is the first step on a path that scientists have carefully mapped out towards the legalization of (genetically modified) babies,” said David King, of anti-gene manipulation group Human Genetics Alert. He spoke last month when the British fertility regulator held its meeting to decide whether to grant the gene-editing license.
 
At an international meeting in Washington last year, scientists agreed that efforts to research the possibility of gene editing should continue, despite the ethical and legal problems the technique raises.
 
Last year, British lawmakers voted to allow scientists to create babies from the DNA of three people to prevent children from inheriting potentially fatal diseases from their mothers. In doing so, it became the first country in the world to allow genetically modified embryos to be transferred into women.
 
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE